CYTODYN INC. DL -,01 WKN: A0YHA5 ISIN: US23283M1018 Kürzel: 296 Forum: Aktien Thema: Hauptdiskussion

submitted to the U.S. Food and Drug Administration next week, Pourhassan said. The study will examine how the drug improves fatigue among other lingering symptoms, he added. Montefiore will be the only New York hospital involved in this study as well as an ongoing phase three trial of leronlimab in severe-to-critical Covid-19 patients, Seethamraju said. The hospital, which recruited 19 patients for the current trial, had also led a phase two trial on mild-to-moderate Covid-19 disease, he added. The trial for severe-to-critical Covid-19 patients, which costs about $9 million, has recruited 247 of its targeted 390 patients, Pourhassan said. The FDA has agreed to review its efficacy results at the 75% recruitment point, which could be hit as soon as next week, Seethamraju said. "This could potentially grant it emergency-use authorization for a segment of Covid-19 patients who don't have any available options," Seethamraju said. Leronlimab is CytoDyn's lead drug candidate and has not yet been approved for any disease. It was originally developed for HIV, cancer and autoimmune disease treatment, but Seethamraju had recommended its development for Covid-19 upon observing benefits with its method of action. CytoDyn, founded in 2000, reported a net loss of $124 million and assets of $50.5 million in the fiscal year that ended May 31.

Gerade gefunden aus dem yah forum

Copied from other board- So biggest things revealed on Today’s conference call are as follows #1 statisticians have provided CD-12 data to FDA. #2 OWS has been in discussions with CYDY and that EAU is on the table especially since FDA now has our data. Expectation is if we get EUA for CD-12 we should get OWS funding help and manufacturing. #3 We also have a unnamed billionaire that if data shows reduces mortality he will personally step in and help with funding. #4 Heavily focused on getting to 293 enrollment currently near 250, significant person Brian B. going around to many of the hospital sites to get us listed as priority. #5 BLA is being worked on for U.K submission still seen as quickest path for approval #6 Long Haulers FDA trial protocol being fine tuned to best position CYDY for future vital indications hopefully submit in a week or so. #7 Canada meeting for HIV next week! #8 Nash hope to enroll patients this year #9 what lawsuits? Oh Bogus investigations what they are

Zusammenfassung von gestern

Na da bin ich ja noch gut dabei mit -6% Wir müssen weiter geduldig sein. Wenn es mit dem HIV Medikament klappt sitzen wir auf einer Goldgrube

Bin mit 40% im Minus, habe nicht aufgepasst .

Hier passiert wohl erstmal nix!

Keine wirklichen News nur Updates, war aber auch zu erwarten 🤔

Und schon was an news raus ?

Na es wäre mal wünschenswert, brauch mal wieder einen richtigen Kracher

Um 22 Uhr geht es los 💪hoffentlich gute News

Bis jetzt waren die Webcast eher negativ für den Kurs 😠hoffentlich heute fett positiv 👍😏

Vielleicht kommt heute Abend mal ein Kracher 👍🏻🍾

Is ja heute sogar ein Stück hoch. Das könnte ja dann vielversprechend sein für die nächste Woche 🙏🏻

Ich denke die Corona Angst hat weniger mit Bio Titeln zu tun , mehr mit Dividenden. Viele Bio's sind gestern gut gestiegen auch ohne news. Wäre schön wenn hier mal eine Top news kommen würde .😉

Ich hab noch viele BioNTech Aktien. Das wird wahrscheinlich mein einziges Zugpferd. Vielleicht kann ich da bald paar Gewinne umverteilen. Sonst alles rot im Moment.